The Efficacy of Cold Atmospheric Plasma Deposited Antibiotics on Titanium Surfaces and Their Elution Liquids Against Staphylococcus aureus Growth Over Time

被引：0
作者：
Olayiwola B. [1 ,2 ]
O’neill F. [2 ]
Kavanagh D.F. [1 ]
O’neill L. [2 ]
O’hara R. [2 ]
机构：
[1] South East Technological University, Carlow
[2] Theradep Inc, San Jose, 95131, CA
来源：
Plasma Medicine | 2023年 / 13卷 / 04期
关键词：
antibiotic efficacy; ciprofloxacin; cold atmospheric plasma; elution testing; penicillin; Staphylococcus aureus;
D O I：
10.1615/PlasmaMed.2023050382
中图分类号：
学科分类号：
摘要：
Cold atmospheric plasma (CAP) was used to deposit antibiotics, penicillin, and ciprofloxacin, separately onto titanium coupons. The antibiotic coating parameters were varied using a design of experiment software which factored in plasma power, bacterial and antibiotic load. The antimicrobial activity of the plasma deposited antibiotics was benchmarked against conventional spray coated materials and the effect of the plasma exposure is discussed. The deposited antibiotics were characterized using various surface analysis and microbiological techniques. It was found that the antibiotics were not degraded and retained antibiotic activity against planktonic Staphylococcus aureus bacteria. However, the presence of the plasma during coating did alter the elution profile of the antibiotics and helped prolong the activity of the antibiotics on the metal surface. This study may contribute to the development of novel implant coating procedures that can offer prolonged antimicrobial protection. © 2023 by Begell House, Inc.
引用
收藏
页码：1 / 20
页数：19
相关论文
共 40 条
  • [1] Tan SY, Tatsumura Y., Alexander Fleming (1881–1955): Discoverer of penicillin, Singapore Med J, 56, 7, pp. 366-367, (2015)
  • [2] Cyphert EL, von Recum HA., Emerging technologies for long-term antimicrobial device coatings: Advantages and limitations, Exp Biol Med, 242, 8, pp. 788-798, (2017)
  • [3] Monegro AF, Muppidi V, Regunath H., Hospital-acquired infections, (2023)
  • [4] Kandi V, Vadakedath S., Implant-associated infections: A review of the safety of cardiac implants, Cureus, 12, 12, (2020)
  • [5] Cerioli M, Batailler C, Conrad A, Roux S, Perpoint T, Becker A, Triffault-Fillit C, Lustig S, Fessy MH, Laurent F, Valour F, Chidiac C, Ferry T., Pseudomonas aeruginosa implant-associated bone and joint infections: Experience in a regional reference center in France, Front Med, 7, (2020)
  • [6] Idrees M, Sawant S, Karodia N, Rahman A., Staphylococcus aureus biofilm: Morphology, genetics, pathogenesis and treatment strategies, Int J Environ Res Public Health, 18, 14, (2021)
  • [7] Romano CL, Tsuchiya H, Morelli I, Battaglia AG, Drago L., Antibacterial coating of implants: Are we missing something?, Bone Joint Res, 8, 5, pp. 199-206, (2019)
  • [8] Castro C, Evora C, Baro M, Soriano I, Sanchez E., Two-month ciprofloxacin implants for multibacterial bone infections, Eur J Pharm Biopharm, 60, 3, pp. 401-406, (2005)
  • [9] Thai T, Salisbury BH, Zito PM., Ciprofloxacin, (2023)
  • [10] Greenberg RN, Kennedy DJ, Reilly PM, Luppen KL, Weinandt WJ, Bollinger MR, Aguirre F, Kodesch F, Saeed AM., Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin, Antimicrob Agents Chemother, 31, 2, pp. 151-155, (1987)
1234